PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsDronabinol
Dronabinol
Dronabinol, Marinol (dronabinol) is a small molecule pharmaceutical. Dronabinol was first approved as Marinol on 1985-05-31. It is used to treat anorexia, nausea, and vomiting in the USA. The pharmaceutical is active against cannabinoid receptor 1. In addition, it is known to target N-arachidonyl glycine receptor, glycine receptor subunit alpha-1, glycine receptor subunit alpha-2, cannabinoid receptor 2, transient receptor potential cation channel subfamily A member 1, G-protein coupled receptor 55, glycine receptor subunit alpha-3, transient receptor potential cation channel subfamily V member 2, and transient receptor potential cation channel subfamily M member 8.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Dronabinol, Marinol (discontinued: Dronabinol, Syndros)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dronabinol
Tradename
Company
Number
Date
Products
MARINOLAlkem LaboratoriesN-018651 RX1985-05-31
3 products, RLD
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
dronabinolNew Drug Application2026-02-11
just cbd - cbd and thc ultra reliefC2002632025-11-17
marinolNew Drug Application2023-02-14
syndrosNew Drug Application2026-01-26
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
vomiting—D014839R11.1
nausea—D009325R11.0
anorexia—D000855R63.0
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Dronabinol, Syndros, Benuvia Operations
82222922028-08-06DS, DP
93457712028-08-06DS, DP
102652932028-08-06DS, DP
112534722028-08-06DS, DP
ATC Codes
A: Alimentary tract and metabolism drugs
— A04: Antiemetics and antinauseants
— A04A: Antiemetics and antinauseants
— A04AD: Other antiemetics in atc
— A04AD10: Dronabinol
HCPCS
Code
Description
Q0167
Dronabinol, 2.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
Clinical
Clinical Trials
613 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Marijuana abuseD002189EFO_0007191F12676410337161
CannabisD002188——4625342599
PainD010146EFO_0003843R521719231259
Healthy volunteers/patients———36——1441
Multiple sclerosisD009103EFO_0003885G3527221130
Wiskott-aldrich syndromeD014923EFO_0003903D82.0912221129
SclerosisD012598———4231128
Muscle spasticityD009128——24131119
Post-traumatic stress disordersD013313EFO_0001358F43.14712415
Alcohol drinkingD000428EFO_0004329——621411
Show 25 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SyndromeD013577——15218—943
Chronic painD059350——31210—629
NeuralgiaD009437EFO_0009430—4813—425
NeoplasmsD009369—C80679—321
Back painD001416—M54148——12
Alzheimer diseaseD000544EFO_0000249F032101——12
NauseaD009325—R11.0263—212
Marijuana useD000074609——371—312
Peripheral nervous system diseasesD010523—G64229——12
Anxiety disordersD001008EFO_0006788F41.1152—411
Show 85 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Substance-related disordersD019966EFO_0003890F13132——520
Driving under the influenceD000066448——74——413
Cognitive dysfunctionD060825—G31.8452——310
Sickle cell anemiaD000755EFO_0000697D5735——28
Hiv infectionsD015658EFO_0000764B2043——17
Mental disordersD001523EFO_0000677F91.923——16
OsteoarthritisD010003EFO_0002506M15-M1915——16
Chediak-higashi syndromeD002609Orphanet_167D72.012——46
Bipolar disorderD001714EFO_0000289F30.921——25
Alcoholic intoxicationD000435——31——25
Show 133 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Psychotic disordersD011618—F20.819———110
PharmacokineticsD010599——5———16
Adolescent behaviorD000294——1———23
Psychomotor disordersD011596——2———13
Tobacco use disorderD014029—F171———12
Drinking behaviorD004327EFO_0004315—1———12
Magnetic resonance imagingD008279——2————2
Psychological codependencyD017004——2————2
Renal insufficiencyD051437—N192————2
Biological availabilityD001682——2————2
Show 31 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Leukocyte-adhesion deficiency syndromeD018370EFO_1001359—————33
Lymphoproliferative disordersD008232Orphanet_2442D47.9————22
Insulin resistanceD007333EFO_0002614E88.819————22
Adolescent developmentD041923——————22
Personality disordersD010554—F60.6————22
Fabry diseaseD000795Orphanet_324E75.21————11
ParalysisD010243——————11
Adult childrenD032721——————11
RehabilitationD012046——————11
X-linked genetic diseasesD040181——————11
Show 55 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDronabinol
INNdronabinol
Description
Delta(9)-tetrahydrocannabinol is a diterpenoid that is 6a,7,8,10a-tetrahydro-6H-benzo[c]chromene substituted at position 1 by a hydroxy group, positions 6, 6 and 9 by methyl groups and at position 3 by a pentyl group. The principal psychoactive constituent of the cannabis plant, it is used for treatment of anorexia associated with AIDS as well as nausea and vomiting associated with cancer chemotherapy. It has a role as a metabolite, a non-narcotic analgesic, a hallucinogen, a cannabinoid receptor agonist and an epitope. It is a diterpenoid, a benzochromene, a polyketide and a phytocannabinoid.
Classification
Small molecule
Drug classcannabinol derivatives
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21
Identifiers
PDB—
CAS-ID1972-08-3
RxCUI—
ChEMBL IDCHEMBL465
ChEBI ID66964
PubChem CID16078
DrugBankDB00470
UNII ID7J8897W37S (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
GLRA2
GLRA2
Organism
Homo sapiens
Gene name
GLRA2
Gene synonyms
NCBI Gene ID
2742
Protein name
glycine receptor subunit alpha-2
Protein synonyms
glycine receptor alpha 2 subunit, glycine receptor, alpha-2 polypeptide
Uniprot ID
Q99862
Mouse ortholog
Glra2 (237213)
glycine receptor subunit alpha-2 (Q7TNC8)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Syndros – Insys Therapeutics
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Dronabinol – Insys Therapeutics
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Dronabinol
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 9,999 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
5,078 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use